Abstract
Raised plasma fibrinogen levels are associated with an increased risk of vascular events. This may be mediated by adverse effects of fibrinogen on plasma viscosity, coagulation, platelet activity, inflammation and atherogenesis. However, there is as yet no drug that specifically lowers plasma fibrinogen levels on a long-term basis. Thus, we do not have intervention trials demonstrating that lowering plasma fibrinogen levels will result in a decreased risk of vascular events. However, such a trial may never happen unless a specific agent is discovered or designed. Several drugs that are used in vascular disease prevention (e.g. lipid lowering agents and antihypertensives) may influence plasma fibrinogen levels. Whether such an additional effect accounts for variations in the benefit resulting from the use of different drugs within the same class remains to be established. The debate continues as to whether fibrinogen is just a marker of vascular risk or whether lowering its circulating levels will result in a significant decrease in clinically relevant endpoints. Whatever the case, the measurement of plasma fibrinogen levels is likely to provide a more comprehensive estimation of risk.
Keywords: Fibrinogen, thrombosis, atherogenesis, platelets, CVD, metabolic syndrome, lipid lowering drugs, antihypertensive drugs, smoking
Current Pharmaceutical Design
Title: Fibrinogen: A Predictor of Vascular Disease
Volume: 13 Issue: 16
Author(s): A. I. Kakafika, E. N. Liberopoulos and D. P. Mikhailidis
Affiliation:
Keywords: Fibrinogen, thrombosis, atherogenesis, platelets, CVD, metabolic syndrome, lipid lowering drugs, antihypertensive drugs, smoking
Abstract: Raised plasma fibrinogen levels are associated with an increased risk of vascular events. This may be mediated by adverse effects of fibrinogen on plasma viscosity, coagulation, platelet activity, inflammation and atherogenesis. However, there is as yet no drug that specifically lowers plasma fibrinogen levels on a long-term basis. Thus, we do not have intervention trials demonstrating that lowering plasma fibrinogen levels will result in a decreased risk of vascular events. However, such a trial may never happen unless a specific agent is discovered or designed. Several drugs that are used in vascular disease prevention (e.g. lipid lowering agents and antihypertensives) may influence plasma fibrinogen levels. Whether such an additional effect accounts for variations in the benefit resulting from the use of different drugs within the same class remains to be established. The debate continues as to whether fibrinogen is just a marker of vascular risk or whether lowering its circulating levels will result in a significant decrease in clinically relevant endpoints. Whatever the case, the measurement of plasma fibrinogen levels is likely to provide a more comprehensive estimation of risk.
Export Options
About this article
Cite this article as:
Kakafika I. A., Liberopoulos N. E. and Mikhailidis P. D., Fibrinogen: A Predictor of Vascular Disease, Current Pharmaceutical Design 2007; 13 (16) . https://dx.doi.org/10.2174/138161207780831310
DOI https://dx.doi.org/10.2174/138161207780831310 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Conserved Pathways: Mitochondrial Dysfunction and Beyond
Current Neurovascular Research Clinical Efficacy of Remdesivir and Favipiravir in the Treatment of COVID-19 Patients: Scenario so far
Current Drug Research Reviews MicroRNAs as Biomarkers for Birth Defects
MicroRNA Cardiovascular Effects of Losartan and Its Relevant Clinical Application
Current Medicinal Chemistry Interindividual Variability in the Efficacy of Oral Antiplatelet Drugs: Definitions, Mechanisms and Clinical Importance
Current Pharmaceutical Design Early Occurrence Cases of Diabetes Mellitus: Clinical Picture in Two Major Tertiary Care Hospitals in India
Current Diabetes Reviews Protein Regulators of Eicosanoid Synthesis: Role in Inflammation
Current Protein & Peptide Science Vascular Endothelial Primary Cilia: Mechanosensation and Hypertension
Current Hypertension Reviews Hyperandrogenism, Insulin Resistance and Hyperinsulinemia as Cardiovascular Risk Factors in Diabetes Mellitus
Current Diabetes Reviews Advances in Peptide Pharmaceuticals
Current Pharmaceutical Biotechnology Obesity, Diabetes and Atrial Fibrillation; Epidemiology, Mechanisms and Interventions
Current Cardiology Reviews Cardiovascular Effects of Metabolic Surgery on Type 2 Diabetes
Current Cardiology Reviews The ATP-driven Hsp60 Machinery: Biological and Clinical Implications
Current Immunology Reviews (Discontinued) Update in Pharmacological Management of Coronary No-Reflow Phenomenon
Cardiovascular & Hematological Agents in Medicinal Chemistry Combating Hepatitis C Virus by Targeting MicroRNA-122 Using Locked Nucleic Acids
Current Gene Therapy Editorial (Thematic Issue: Is The Female Heart Exposed To Cardiovascular Disease?)
Current Medicinal Chemistry Soy Isoflavones and Cardiovascular Health: An Update
Current Nutrition & Food Science Circulating Endothelial Progenitor Cells Biology and Regenerative Medicine in Pulmonary Vascular Diseases
Current Pharmaceutical Biotechnology Calcium Antagonists: A Ready Prescription for Treating Infectious Diseases?
Current Topics in Medicinal Chemistry Novel Biomarkers Assessing the Calcium Deposition in Coronary Artery Disease
Current Medicinal Chemistry